Skip to main content
. Author manuscript; available in PMC: 2022 Jan 1.
Published in final edited form as: Mol Cancer Res. 2021 Apr 16;19(7):1137–1145. doi: 10.1158/1541-7786.MCR-21-0099

Figure 3: Constitutive overexpression of p65 blocks DMAPT-induced reduction of AR-V7 expression and function.

Figure 3:

(A) Protein expression of phos-p65, p65 and AR-V7 by western blot comparing parental LNCaP-95 and 22Rv1 cell lines with lines stably expressing empty vector or p65 overexpression vector. (B) AR-V7 and AR-FL mRNA expression in LNCaP-95 and 22Rv1 cells overexpressing p65 compared to control cell lines (parental and empty vector) ± DMAPT treatment (5μM for 72 hours, n = 3 in technical triplicate, error bars +/−1SEM). (C) Basal expression of AR-V7 specific targets, ETS2 and EDN2, ± DMAPT treatment (5μM for 72 hours) ± p56 overexpression (n = 2 in technical triplicate and repeated once, error bars +/−1SEM). D) R1881-stimulated expression on AR targets, FKBP5 and KLK3 ± DMAPT treatment (5μM for 72 hours) ± p65 overexpression (n = 2 in technical triplicate and repeated once, error bars +/−1SEM). * p<0.05, **p<0.01, ***p<0.001.